Table 1. Clinical–pathological details of patients included in the analysis.
| Sex | Males | 22/30 (73%) |
|---|---|---|
| Females | 8/30 (27%) | |
| Tumour primary site | Parotid gland | 22/30 (73%) |
| Submandibular gland | 5/30 (17%) | |
| Sublingual and minor salivary glands | 3/30 (10%) | |
| Tumour histopathology | ACC | 11/30 (37%) |
| SDC | 11/30 (37%) | |
| MEC | 7/30 (23%) | |
| MASC | 1/30 (3%) | |
| Disease stage at presentation | Recurrent advanced | 17/30 (57%) |
| Upfront advanced | 13/30 ( 43%) | |
| Metastatic sites | Lungs | 17/30 (57%) |
| Bone | 7/30 (23%) |